Gilead Sciences, Inc. (GILD) stock prices updated...
 

Gilead Sciences, Inc. stock price

Gilead Sciences, Inc. latest news:


  • 10/26/2017 16:35:19

    UPDATE 2-Gilead weak hepatitis C sales outlook sends shares lower

    Oct 26 (Reuters) - Gilead Sciences Inc posted better-than-expected third-quarter profit on Thursday, but shares fell after hours as use of its flagship hepatitis C drugs waned further and the company said it expects to feel the full impact of more competition in the current quarter.

  • 10/26/2017 15:30:55

    UPDATE 1-Gilead profit beats estimates, but shares drop after hours

    Oct 26 (Reuters) - Gilead Sciences Inc posted better-than-expected third-quarter profits on Thursday, but shares fell after hours as use of its flagship hepatitis C drugs waned further and the company said it had yet to feel the full impact of more competition.

  • 10/26/2017 14:13:37

    Gilead shares higher after earnings, revenue beat

    Shares of Gilead Sciences Inc. rose 0.2% late Thursday after the pharma company reported adjusted third-quarter earnings and revenue above expectations. Gilead said it earned $2.7 billion, or $2.06 a share, in the quarter, compared with $3.3 billion, or $2.49 a share, in the year-ago period. Adjusted for one-time items, the company earned $3 billion, or $2.27 a share, compared with $3.7 billion, or $2.75 a diluted share, a year ago. Revenue fell to $6.5 billion, compared with $7.5 billion a year ago. Analysts polled by FactSet had expected Gilead to post adjusted earnings of $2.13 a share on sales of $6.4 billion. The company expects net product sales between $24.5 billion and $25.5 billion for the year, compared with a previous estimate of sales in a range from $24 billion to $25.5 billion. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/18/2017 15:51:54

    FDA approves Gilead's Yescarta cancer immunotherapy

    Oct 18 (Reuters) - A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of schedule.

  • 09/28/2017 13:51:47

    Gilead shares decline nearly 5% after COO says he will retire

    Gilead Sciences Inc. shares declined 4.7% in extremely heavy trade on Thursday following an announcement the day prior that the company's Chief Operating Officer Kevin Young plans to retire in early 2018. The share weakness could be attributed to that news, said Credit Suisse analyst Alethia Young, adding that she doesn't believe the timing "bodes negative for Gilead." Gilead's Kevin Young had previously retired and returned to work to "help the company through some specific goals," including the company's $11 billion Kite Pharma acquisition, announced last month, according to Credit Suisse's Alethia Young, who spoke with the company. "We think it makes sense that Kevin Young likely came back to the company to help the company in a time of a crossroads ahead of their next major acquisition, but we were never under the impression that he would be permanently back at the company," Alethia Young said, and the company told her that it has operated without a COO before. Kevin Young has been with Gilead since 2004; after he retired in 2014, he returned to the company as COO last year. He plans to continue advising the company after he retires, according to Gilead. Alethia Young rates Gilead outperform with an $85 price target. Gilead shares surged 11.5% to $80.21 over the last three months, compared with a 2.8% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/27/2017 18:16:25

    BRIEF-Kevin Young to retire as Gilead Sciences COO

    * Kevin Young CBE, chief operating officer, plans to retire, effective early 2018‚Äč

  • 08/31/2017 11:50:59

    Biotech ETF on track for fourth straight daily rise, hits highest level since 2015

    The largest exchange-traded fund to track the biotechnology sector rallied on Thursday, moving in its biggest one-day percentage pop since June as it hit levels not seen since early 2016. The iShares Nasdaq Biotechnology ETF jumped 2.3% to $331.62, and earlier rose as high as $333.30. That represented the highest level for the fund since the last trading day of 2015, according to FactSet data. The ETF has been a strong performer of late. Thursday is set to be its fourth straight daily increase; for the week it is up 6.6%, on pace for its biggest weekly gain since June. Among the fund's biggest gainers, Biogen Inc. added 3.9% while BioMarin Pharmaceutical Inc. was up 2.2% and Gilead Sciences added 2.1%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 14:02:46

    U.S. stocks end higher; Nasdaq boosted by biotech gain

    U.S. stocks ended higher on Wednesday, with the Nasdaq seeing a particular gain on the strength of biotechnology companies, while the S&P 500 closed higher for a fourth straight session. The Dow Jones Industrial Average rose 25 points, or 0.1%, to 21,890. The S&P 500 added 11 points to 2,457, a gain of 0.5%. The Nasdaq Composite Index advanced 66 points to 6,368, a rise of 1.1%. The biotechnology sector was one of the strongest of the day, with the iShares Nasdaq Biotechnology ETF up 1.9%, boosted by Gilead Sciences , which surged 7.3%, and Incyte Corp. , up 10.6%. Markets were also supported by strong economic data, including better-than-expected reads on economic growth and private-sector employment. The Dow was pressured by Travelers Companies Inc. , which fell 1%, and by Verizon Communications , which was off 0.8%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 09:29:54

    Biotech stocks rally, ETF on track for third straight daily gain

    Biotechnology stocks rallied on Wednesday, with one of the biggest exchange-traded funds dedicated to the sector on track for its third straight daily advance. The iShares Nasdaq Biotechnology ETF gained 1.3%, bringing its week-to-date rise to 3.6%. Among the biggest gainers in the sector, Gilead Sciences Inc. popped 5.6%, bringing its gain over the past three months to 23.7%. The stock is on track for its largest percentage gain since November, as well as its highest close since September 2016. Separately, Incyte Corp. added 4.5% while BioMarin Pharmaceutical Inc. advanced 4.8%. Biogen Inc. gained 2.4% while Regeneron Pharmaceuticals Inc. was up 2%. On the downside within the pharmaceutical sector, U.S.-listed shares of Novartis AG were down 1%. The company's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 09:21:49

    Novartis AG's CAR-T cell therapy for leukemia approved by FDA in 'historic action'; price to be based on outcomes

    Novartis AG's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people up to age 25 with a form of acute lymphoblastic leukemia. CAR-T, or chimeric antigen receptor T-cell therapy, uses a patient's immune T-cells and re-engineers them to better fight cancer. As such, each dose of Kymriah is customized to the individual patient's T-cells through genetic modification. Novartis said on Wednesday that it will work with the Centers for Medicare and Medicaid Services so medicine prices can be "based on the clinical outcomes achieved, which would eliminate inefficiencies from the health care system." For Kymriah, Novartis is also working with CMS "to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month." Novartis did not give any specifics as to what the price range might be. Even before Novartis' Kymriah was approved, there was concern about pricing of the new therapy, given that new therapies are typically priced based on level of innovation and cancer is a particularly expensive area. On Wednesday, the FDA also expanded approval of Roche's Genentech's rheumatoid arthritis drug Actemra to treat CAR-T cell-induced cytokine release syndrome, which consists of high fever and flu-like symptoms and can be life-threatening; nearly 70% of patients had CRS completely resolved in two weeks using one or two doses of Actemra, the FDA said. Kite Pharma, which is also working in the CAR-T space, has also been racing to gain FDA approval; the biotech's $11 billion acquisition by Gilead Sciences Inc. was reported earlier this week. Gilead shares surged 5.5% in extremely heavy midday trade. Novartis shares declined 1% in heavy midday trade. Novartis shares have risen 2.8% over the last three months, compared with a 1.6% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/28/2017 13:02:05

    Gilead Sciences to buy Kite Pharma for $11.9B to expand cancer drug lineup

    Gilead Sciences to buy Kite Pharma for $11.9B to expand cancer drug lineup        

  • 08/28/2017 13:01:49

    Jim Cramer reacts to the Gilead Sciences-Kite Pharma acquisition

    Gilead Sciences agreed to acquire Kite Pharma for $11.9 billion on Monday, sending shares of both stocks higher. Video provided by TheStreet        

  • 08/28/2017 11:39:53

    Stocks decline as storm pressures insurers and oil companies

    U.S. stocks are rising Monday morning, with health care companies making some of the largest gains after biotechnology company Gilead Sciences agreed to buy cancer drug maker Kite Pharma for $11.9 billion.

  • 08/28/2017 11:37:28

    Gilead to pay $11.9B for cancer treatment developer Kite

    Gilead Sciences is buying Kite Pharma for $11.9 billion, giving the biotechnology company a broader portfolio of potential cell therapies for cancer.

  • 08/28/2017 09:41:09

    Biotech stocks surge on Gilead's Kite Pharma acquisition

    After news of Gilead Sciences Inc.'s about $11 billion acquisition of Kite Pharma Inc. , Juno Therapeutics Inc. shares surged 16.3%, Bluebird Bio Inc. shares surged 9.7% and Cellectis SA ADR shares surged 11.8% in extremely heavy midday trade Monday. The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T-cell therapy, or CAR-T, which uses a patient's immune T-cells and re-engineers them to better fight cancer. Juno, Bluebird and Cellectis are other biotech companies working in CAR-T. BTIF analyst Dane Leone upgraded Juno on Monday, adding, "we continue to be skeptical of JUNO's current competitive positioning, but upgrade our ranking to Neutral from Sell, as there is not a near term catalyst to offset the positive tailwind for the entire CAR T space." Though there has been speculation about Celgene -- which owns about 10% of Juno's current shares outstanding -- acquiring Juno, "we would be surprised" by a full acquisition, Leone said, since "at this juncture with emerging overlap in Multiple Myeloma and third to market status in CD19 hematological malignancies, we struggle to find a rationale for Celgene wanting to fully own Juno." Kite Pharma shares surged 28% in extremely heavy morning trade. Shares have surged 144% over the last three months, compared with a 1% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Glacier Bancorp, Inc.GBCI | Gladstone Capital CorporationGLAD | Gladstone Capital CorporationGLADO | Gladstone Commercial CorporationGOOD | Gladstone Commercial CorporationGOODN | Gladstone Commercial CorporationGOODO | Gladstone Commercial CorporationGOODP | Gladstone Investment CorporationGAIN | Gladstone Investment CorporationGAINN | Gladstone Investment CorporationGAINO |